Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Biden announces plans for U.S. to buy 200M extra COVID-19 doses » 17:41
01/26/21
01/26
17:41
01/26/21
17:41
PFE

Pfizer

$37.31 /

+0.025 (+0.07%)

, BNTX

BioNTech

$106.18 /

-4.355 (-3.94%)

, MRNA

Moderna

$151.85 /

+4.85 (+3.30%)

, SPX

S&P 500

$0.00 /

+ (+0.00%)

, SPY

SPDR S&P 500 ETF Trust

$383.82 /

-0.58 (-0.15%)

U.S. President Joe Biden…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PFE Pfizer
$37.31 /

+0.025 (+0.07%)

BNTX BioNTech
$106.18 /

-4.355 (-3.94%)

MRNA Moderna
$151.85 /

+4.85 (+3.30%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SPY SPDR S&P 500 ETF Trust
$383.82 /

-0.58 (-0.15%)

PFE Pfizer
$37.31 /

+0.025 (+0.07%)

01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
01/14/21 Oppenheimer
Essa Pharma price target raised to $20 from $9 at Oppenheimer
01/05/21 Argus
Viatris initiated with a Hold at Argus
12/31/20 Ladenburg
UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg
BNTX BioNTech
$106.18 /

-4.355 (-3.94%)

01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
12/29/20 Citi
Arcturus selloff brings 'very good' buying opportunity, says Citi
12/22/20 Roth Capital
Translate Bio price target raised to $37 from $30 at Roth Capital
12/15/20 Jefferies
Jefferies starts Maravai at Buy, says 'more than just a COVID vaccine play'
MRNA Moderna
$151.85 /

+4.85 (+3.30%)

01/25/21 Piper Sandler
Piper reiterates $170 target on Moderna with vaccine active on new strains
01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
01/06/21 Piper Sandler
Moderna price target raised to $170 after EU vaccine approval at Piper Sandler
01/04/21 Piper Sandler
Moderna shares warrant 'fresh look' after 41% pullback, says Piper Sandler
SPX S&P 500
$0.00 /

+ (+0.00%)

01/07/21 Credit Suisse
Credit Suisse raises 2021 S&P 500 target to 4,200, sees 12% upside
11/09/20 JPMorgan
JPMorgan sees S&P 500 hitting 4,000 by early next year
09/01/20
Fed's Brainard says monetary policy to pivot from stabilization to accommodation
08/17/20 Goldman Sachs
Goldman boosts end of 2020 S&P 500 target to 3,600 from 3,000
SPY SPDR S&P 500 ETF Trust
$383.82 /

-0.58 (-0.15%)

01/07/21 Credit Suisse
Credit Suisse raises 2021 S&P 500 target to 4,200, sees 12% upside
11/09/20 JPMorgan
JPMorgan sees S&P 500 hitting 4,000 by early next year
09/01/20
Fed's Brainard says monetary policy to pivot from stabilization to accommodation
08/17/20 Goldman Sachs
Goldman boosts end of 2020 S&P 500 target to 3,600 from 3,000
PFE Pfizer
$37.31 /

+0.025 (+0.07%)

BNTX BioNTech
$106.18 /

-4.355 (-3.94%)

MRNA Moderna
$151.85 /

+4.85 (+3.30%)

  • 23
    Jul
  • 19
    May
  • 12
    Feb
  • 06
    Feb
PFE Pfizer
$37.31 /

+0.025 (+0.07%)

BNTX BioNTech
$106.18 /

-4.355 (-3.94%)

MRNA Moderna
$151.85 /

+4.85 (+3.30%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SPY SPDR S&P 500 ETF Trust
$383.82 /

-0.58 (-0.15%)

PFE Pfizer
$37.31 /

+0.025 (+0.07%)

BNTX BioNTech
$106.18 /

-4.355 (-3.94%)

MRNA Moderna
$151.85 /

+4.85 (+3.30%)

PFE Pfizer
$37.31 /

+0.025 (+0.07%)

BNTX BioNTech
$106.18 /

-4.355 (-3.94%)

MRNA Moderna
$151.85 /

+4.85 (+3.30%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SPY SPDR S&P 500 ETF Trust
$383.82 /

-0.58 (-0.15%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SPY SPDR S&P 500 ETF Trust
$383.82 /

-0.58 (-0.15%)

Options
BioNTech SE put volume heavy and directionally bearish » 14:35
01/26/21
01/26
14:35
01/26/21
14:35
BNTX

BioNTech

$108.08 /

-2.455 (-2.22%)

Bearish flow noted in…

Bearish flow noted in BioNTech SE with 6,301 puts trading, or 2x expected. Most active are Feb-21 80 puts and Feb-21 65 puts, with total volume in those strikes near 4,100 contracts. The Put/Call Ratio is 3.30, while ATM IV is up over 1 point on the day. Earnings are expected on March 30th.

ShowHide Related Items >><<
BNTX BioNTech
$108.08 /

-2.455 (-2.22%)

BNTX BioNTech
$108.08 /

-2.455 (-2.22%)

01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
12/29/20 Citi
Arcturus selloff brings 'very good' buying opportunity, says Citi
12/22/20 Roth Capital
Translate Bio price target raised to $37 from $30 at Roth Capital
12/15/20 Jefferies
Jefferies starts Maravai at Buy, says 'more than just a COVID vaccine play'
BNTX BioNTech
$108.08 /

-2.455 (-2.22%)

  • 23
    Jul
  • 06
    Feb
BNTX BioNTech
$108.08 /

-2.455 (-2.22%)

BNTX BioNTech
$108.08 /

-2.455 (-2.22%)

BNTX BioNTech
$108.08 /

-2.455 (-2.22%)

Recommendations
Amarin in 'strong position' against Health Net, says Piper Sandler » 10:35
01/26/21
01/26
10:35
01/26/21
10:35
AMRN

Amarin

$7.38 /

-0.17 (-2.25%)

, GSK

GlaxoSmithKline

$39.12 /

+0.21 (+0.54%)

, TEVA

Teva

$12.33 /

-0.065 (-0.52%)

Amarin (AMRN) yesterday…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TEVA Teva
$12.33 /

-0.065 (-0.52%)

GSK GlaxoSmithKline
$39.12 /

+0.21 (+0.54%)

AMRN Amarin
$7.38 /

-0.17 (-2.25%)

AMRN Amarin
$7.38 /

-0.17 (-2.25%)

01/25/21 Cantor Fitzgerald
Cantor says Amarin opportunity for Vascepa outside U.S. still 'underappreciated'
01/25/21 Piper Sandler
Piper Sandler reiterates 'conviction call' on Amarin into European decision
01/22/21 Cowen
Amarin remains undervalued under almost any scenario, says Cowen
01/08/21 Piper Sandler
Piper sees 're-birth' for Amarin shares in 2021, keeps $19 price target
GSK GlaxoSmithKline
$39.12 /

+0.21 (+0.54%)

01/20/21 UBS
GlaxoSmithKline price target raised to 1,450 GBp from 1,440 GBp at UBS
01/20/21
Fly Intel: Top five analyst downgrades
01/20/21 Credit Suisse
GlaxoSmithKline downgraded to Underperform from Neutral at Credit Suisse
01/20/21 Credit Suisse
GlaxoSmithKline downgraded to Underperform from Neutral at Credit Suisse
TEVA Teva
$12.33 /

-0.065 (-0.52%)

12/21/20 Gabelli
Teva named 'Best Idea for 2021' at Gabelli
11/27/20 H.C. Wainwright
Corcept Therapeutics price target raised to $32 from $22 at H.C. Wainwright
11/24/20 Oppenheimer
Teva initiated with a Perform at Oppenheimer
11/23/20 Citi
Citi recommends pair trade of overweight Endo, underweight Teva
TEVA Teva
$12.33 /

-0.065 (-0.52%)

GSK GlaxoSmithKline
$39.12 /

+0.21 (+0.54%)

AMRN Amarin
$7.38 /

-0.17 (-2.25%)

TEVA Teva
$12.33 /

-0.065 (-0.52%)

GSK GlaxoSmithKline
$39.12 /

+0.21 (+0.54%)

AMRN Amarin
$7.38 /

-0.17 (-2.25%)

TEVA Teva
$12.33 /

-0.065 (-0.52%)

GSK GlaxoSmithKline
$39.12 /

+0.21 (+0.54%)

AMRN Amarin
$7.38 /

-0.17 (-2.25%)

TEVA Teva
$12.33 /

-0.065 (-0.52%)

GSK GlaxoSmithKline
$39.12 /

+0.21 (+0.54%)

AMRN Amarin
$7.38 /

-0.17 (-2.25%)

Hot Stocks
Amarin expands Vascepa patent infringement suit to include Health Net » 10:32
01/26/21
01/26
10:32
01/26/21
10:32
AMRN

Amarin

$7.40 /

-0.15 (-1.99%)

, HKMPF

Hikma Pharmaceuticals

$0.00 /

+ (+0.00%)

Amarin (AMRN) last night…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

AMRN Amarin
$7.40 /

-0.15 (-1.99%)

AMRN Amarin
$7.40 /

-0.15 (-1.99%)

01/25/21 Cantor Fitzgerald
Cantor says Amarin opportunity for Vascepa outside U.S. still 'underappreciated'
01/25/21 Piper Sandler
Piper Sandler reiterates 'conviction call' on Amarin into European decision
01/22/21 Cowen
Amarin remains undervalued under almost any scenario, says Cowen
01/08/21 Piper Sandler
Piper sees 're-birth' for Amarin shares in 2021, keeps $19 price target
HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

01/25/21 Peel Hunt
Hikma Pharmaceuticals downgraded to Hold from Buy at Peel Hunt
01/05/21 Citi
Underlying trends for Hikma point to upside risks, says Citi
11/24/20 JPMorgan
Hikma Pharmaceuticals price target raised to 3,000 GBp from 2,400 GBp at JPMorgan
09/22/20 Morgan Stanley
Hikma Pharmaceuticals downgraded to Equal Weight from Overweight at Morgan Stanley
AMRN Amarin
$7.40 /

-0.15 (-1.99%)

AMRN Amarin
$7.40 /

-0.15 (-1.99%)

AMRN Amarin
$7.40 /

-0.15 (-1.99%)

AMRN Amarin
$7.40 /

-0.15 (-1.99%)

Periodicals
Pfizer sees ability to deliver vaccine faster than expected, Bloomberg reports » 09:37
01/26/21
01/26
09:37
01/26/21
09:37
PFE

Pfizer

$37.28 /

+0.74 (+2.03%)

, BNTX

BioNTech

$110.62 /

+2.33 (+2.15%)

Pfizer (PFE) CEO Albert…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PFE Pfizer
$37.28 /

+0.74 (+2.03%)

BNTX BioNTech
$110.62 /

+2.33 (+2.15%)

PFE Pfizer
$37.28 /

+0.74 (+2.03%)

01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
01/14/21 Oppenheimer
Essa Pharma price target raised to $20 from $9 at Oppenheimer
01/05/21 Argus
Viatris initiated with a Hold at Argus
12/31/20 Ladenburg
UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg
BNTX BioNTech
$110.62 /

+2.33 (+2.15%)

12/29/20 Citi
Arcturus selloff brings 'very good' buying opportunity, says Citi
12/22/20 Roth Capital
Translate Bio price target raised to $37 from $30 at Roth Capital
12/15/20 Jefferies
Jefferies starts Maravai at Buy, says 'more than just a COVID vaccine play'
PFE Pfizer
$37.28 /

+0.74 (+2.03%)

BNTX BioNTech
$110.62 /

+2.33 (+2.15%)

  • 23
    Jul
  • 06
    Feb
PFE Pfizer
$37.28 /

+0.74 (+2.03%)

BNTX BioNTech
$110.62 /

+2.33 (+2.15%)

PFE Pfizer
$37.28 /

+0.74 (+2.03%)

BNTX BioNTech
$110.62 /

+2.33 (+2.15%)

PFE Pfizer
$37.28 /

+0.74 (+2.03%)

BNTX BioNTech
$110.62 /

+2.33 (+2.15%)

Yesterday
Hot Stocks
Minnesota DOH reports first U.S. case of COVID-19 variant first found in Brazil » 17:37
01/25/21
01/25
17:37
01/25/21
17:37
SPX

S&P 500

$0.00 /

+ (+0.00%)

, SPY

SPDR S&P 500 ETF Trust

$384.40 /

+1.55 (+0.40%)

, PFE

Pfizer

$37.28 /

+0.74 (+2.03%)

, BNTX

BioNTech

$110.62 /

+2.33 (+2.15%)

, MRNA

Moderna

$147.00 /

+15.95 (+12.17%)

, AZN

AstraZeneca

$54.02 /

+0.76 (+1.43%)

, JNJ

Johnson & Johnson

$165.91 /

+2.23 (+1.36%)

, NVAX

Novavax

$131.47 /

+4.48 (+3.53%)

The Minnesota Department…

The Minnesota Department of Health announced that its Public Health Laboratory has found the variant of the SARS-CoV-2 virus known as the Brazil P.1 variant in a specimen from a Minnesota resident with recent travel history to Brazil. While this variant is thought to be more transmissible than the initial strain of the virus that causes COVID-19 disease, it is not yet known whether the variant causes more severe illness. This case marks the first documented instance of the Brazil P.1 variant in the United States. The variant was found through the MDH's variant surveillance program. Each week this program collects 50 random samples from the University of Minnesota clinical laboratories, Infinity Biologix Laboratory in Oakdale, and other testing partners and then conducts special testing using a process called whole genome sequencing. Through this program, the state develops a more accurate picture of what specific forms of COVID-19 are circulating in Minnesota. Companies in the COVID-19 vaccine space include Pfizer (PFE), BioNTech (BNTX), Moderna (MRNA), AstraZeneca (AZN), Johnson & Johnson (JNJ), and Novavax (NVAX). Reference Link

ShowHide Related Items >><<
SPX S&P 500
$0.00 /

+ (+0.00%)

PFE Pfizer
$37.28 /

+0.74 (+2.03%)

NVAX Novavax
$131.47 /

+4.48 (+3.53%)

MRNA Moderna
$147.00 /

+15.95 (+12.17%)

JNJ Johnson & Johnson
$165.91 /

+2.23 (+1.36%)

BNTX BioNTech
$110.62 /

+2.33 (+2.15%)

AZN AstraZeneca
$54.02 /

+0.76 (+1.43%)

SPX S&P 500
$0.00 /

+ (+0.00%)

01/07/21 Credit Suisse
Credit Suisse raises 2021 S&P 500 target to 4,200, sees 12% upside
11/09/20 JPMorgan
JPMorgan sees S&P 500 hitting 4,000 by early next year
09/01/20
Fed's Brainard says monetary policy to pivot from stabilization to accommodation
08/17/20 Goldman Sachs
Goldman boosts end of 2020 S&P 500 target to 3,600 from 3,000
SPY SPDR S&P 500 ETF Trust
$384.40 /

+1.55 (+0.40%)

PFE Pfizer
$37.28 /

+0.74 (+2.03%)

01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
01/14/21 Oppenheimer
Essa Pharma price target raised to $20 from $9 at Oppenheimer
01/05/21 Argus
Viatris initiated with a Hold at Argus
12/31/20 Ladenburg
UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg
BNTX BioNTech
$110.62 /

+2.33 (+2.15%)

12/29/20 Citi
Arcturus selloff brings 'very good' buying opportunity, says Citi
12/22/20 Roth Capital
Translate Bio price target raised to $37 from $30 at Roth Capital
12/15/20 Jefferies
Jefferies starts Maravai at Buy, says 'more than just a COVID vaccine play'
MRNA Moderna
$147.00 /

+15.95 (+12.17%)

01/25/21 Piper Sandler
Piper reiterates $170 target on Moderna with vaccine active on new strains
01/06/21 Piper Sandler
Moderna price target raised to $170 after EU vaccine approval at Piper Sandler
01/04/21 Piper Sandler
Moderna shares warrant 'fresh look' after 41% pullback, says Piper Sandler
AZN AstraZeneca
$54.02 /

+0.76 (+1.43%)

01/22/21 Barclays
AstraZeneca price target lowered to 9,000 GBp from 9,300 GBp at Barclays
01/19/21 BTIG
Adaptive Biotechnologies price target raised to $74 from $66 at BTIG
01/15/21 Berenberg
AstraZeneca price target lowered to 10,000 GBp from 10,500 GBp at Berenberg
01/15/21
Fly Intel: Top five analyst initiations
JNJ Johnson & Johnson
$165.91 /

+2.23 (+1.36%)

01/15/21 B. Riley Securities
Arcturus Therapeutics downgraded to Neutral from Buy at B. Riley Securities
12/29/20 Piper Sandler
Piper still believes in Arcturus vaccine after 'underwhelming' immunogenicity
NVAX Novavax
$131.47 /

+4.48 (+3.53%)

12/29/20 B. Riley Securities
Novavax selloff yesterday brings 'compelling' opportunity, says B. Riley
12/28/20 JPMorgan
JPMorgan sees data from Novavax vaccine trial in U.S. in March/April
12/14/20 Jefferies
Novavax initiated with a Buy at Jefferies
12/07/20 B. Riley Securities
Arcturus Therapeutics price target raised to $111 from $64 at B. Riley
PFE Pfizer
$37.28 /

+0.74 (+2.03%)

NVAX Novavax
$131.47 /

+4.48 (+3.53%)

MRNA Moderna
$147.00 /

+15.95 (+12.17%)

JNJ Johnson & Johnson
$165.91 /

+2.23 (+1.36%)

BNTX BioNTech
$110.62 /

+2.33 (+2.15%)

AZN AstraZeneca
$54.02 /

+0.76 (+1.43%)

  • 23
    Jul
  • 19
    May
  • 12
    Feb
  • 06
    Feb
SPX S&P 500
$0.00 /

+ (+0.00%)

PFE Pfizer
$37.28 /

+0.74 (+2.03%)

NVAX Novavax
$131.47 /

+4.48 (+3.53%)

MRNA Moderna
$147.00 /

+15.95 (+12.17%)

JNJ Johnson & Johnson
$165.91 /

+2.23 (+1.36%)

BNTX BioNTech
$110.62 /

+2.33 (+2.15%)

AZN AstraZeneca
$54.02 /

+0.76 (+1.43%)

PFE Pfizer
$37.28 /

+0.74 (+2.03%)

NVAX Novavax
$131.47 /

+4.48 (+3.53%)

MRNA Moderna
$147.00 /

+15.95 (+12.17%)

JNJ Johnson & Johnson
$165.91 /

+2.23 (+1.36%)

BNTX BioNTech
$110.62 /

+2.33 (+2.15%)

AZN AstraZeneca
$54.02 /

+0.76 (+1.43%)

SPY SPDR S&P 500 ETF Trust
$384.40 /

+1.55 (+0.40%)

SPX S&P 500
$0.00 /

+ (+0.00%)

PFE Pfizer
$37.28 /

+0.74 (+2.03%)

NVAX Novavax
$131.47 /

+4.48 (+3.53%)

MRNA Moderna
$147.00 /

+15.95 (+12.17%)

JNJ Johnson & Johnson
$165.91 /

+2.23 (+1.36%)

BNTX BioNTech
$110.62 /

+2.33 (+2.15%)

AZN AstraZeneca
$54.02 /

+0.76 (+1.43%)

SPY SPDR S&P 500 ETF Trust
$384.40 /

+1.55 (+0.40%)

SPX S&P 500
$0.00 /

+ (+0.00%)

Recommendations
Cantor says Amarin opportunity for Vascepa outside U.S. still 'underappreciated' » 16:03
01/25/21
01/25
16:03
01/25/21
16:03
AMRN

Amarin

$7.59 /

+1.025 (+15.63%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Louise Chen noted that the EU's CHMP published its agenda for meetings taking place this week, which includes reference to icosapent ethyl. The meeting timing puts Amarin in-line to "on the earlier side" of potentially receiving a CHMP opinion that it has said would occur in late January to early February of this year, according to Chen, who expects a positive CHMP opinion and for EMA approval to follow within 67 days of a CHMP decision. Chen, who thinks recent updates highlight the "underappreciated opportunities" for Vascepa outside of the U.S., keeps an Overweight rating on Amarin shares with a $10 price target.

ShowHide Related Items >><<
AMRN Amarin
$7.59 /

+1.025 (+15.63%)

AMRN Amarin
$7.59 /

+1.025 (+15.63%)

01/25/21 Piper Sandler
Piper Sandler reiterates 'conviction call' on Amarin into European decision
01/22/21 Cowen
Amarin remains undervalued under almost any scenario, says Cowen
01/08/21 Piper Sandler
Piper sees 're-birth' for Amarin shares in 2021, keeps $19 price target
12/28/20 Cantor Fitzgerald
Vascepa showing positive year-over-year trends, says Cantor Fitzgerald
AMRN Amarin
$7.59 /

+1.025 (+15.63%)

AMRN Amarin
$7.59 /

+1.025 (+15.63%)

AMRN Amarin
$7.59 /

+1.025 (+15.63%)

AMRN Amarin
$7.59 /

+1.025 (+15.63%)

Hot Stocks
BioNTech, Shanghai Fosun receive Hong Kong approval for Covid vaccine » 12:22
01/25/21
01/25
12:22
01/25/21
12:22
BNTX

BioNTech

$108.58 /

+0.29 (+0.27%)

, SFOSF

Shanghai Fosun

$0.00 /

+ (+0.00%)

BioNTech (BNTX) and…

BioNTech (BNTX) and Shanghai Fosun Pharmaceutical (SFOSF) announced that according to the Food and Health Bureau of the Hong Kong Special Administrative Region, the COVID-19 vaccine Comirnaty ased on BioNTech's mRNA technology has received authorization for emergency use in Hong Kong. The vaccine will be produced in BioNTech's manufacturing facilities in Germany, and supplied to Hong Kong for administration under the Hong Kong SAR Government's COVID-19 Vaccination Program.

ShowHide Related Items >><<
BNTX BioNTech
$108.58 /

+0.29 (+0.27%)

BNTX BioNTech
$108.58 /

+0.29 (+0.27%)

01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
12/29/20 Citi
Arcturus selloff brings 'very good' buying opportunity, says Citi
12/22/20 Roth Capital
Translate Bio price target raised to $37 from $30 at Roth Capital
12/15/20 Jefferies
Jefferies starts Maravai at Buy, says 'more than just a COVID vaccine play'
SFOSF Shanghai Fosun
$0.00 /

+ (+0.00%)

BNTX BioNTech
$108.58 /

+0.29 (+0.27%)

  • 23
    Jul
  • 06
    Feb
BNTX BioNTech
$108.58 /

+0.29 (+0.27%)

BNTX BioNTech
$108.58 /

+0.29 (+0.27%)

BNTX BioNTech
$108.58 /

+0.29 (+0.27%)

Recommendations
Piper Sandler reiterates 'conviction call' on Amarin into European decision » 08:46
01/25/21
01/25
08:46
01/25/21
08:46
AMRN

Amarin

$6.56 /

+0.255 (+4.04%)

Piper Sandler analyst…

Piper Sandler analyst Yasmeen Rahimi reiterates reiterate her "conviction call" on Amarin's potential for European approval of Vascepa, with the Committee for Medicinal Products for Human Use opinion expected in late January or February. Potential European Medicines Agency approval 67 days after the CHMP recommendation is the most important stock-moving catalyst for Amarin shares in 2021, Rahimi tells investors in a research note. She continues to believe Amarin will have a "re-birth" in 202 on Vascepa's continued revenue growth and global market opportunity. The analyst keeps an Overweight rating on the shares with a $19 price target.

ShowHide Related Items >><<
AMRN Amarin
$6.56 /

+0.255 (+4.04%)

AMRN Amarin
$6.56 /

+0.255 (+4.04%)

01/22/21 Cowen
Amarin remains undervalued under almost any scenario, says Cowen
01/08/21 Piper Sandler
Piper sees 're-birth' for Amarin shares in 2021, keeps $19 price target
12/28/20 Cantor Fitzgerald
Vascepa showing positive year-over-year trends, says Cantor Fitzgerald
12/23/20 Goldman Sachs
Amarin price target lowered to $6 from $8 at Goldman Sachs
AMRN Amarin
$6.56 /

+0.255 (+4.04%)

AMRN Amarin
$6.56 /

+0.255 (+4.04%)

AMRN Amarin
$6.56 /

+0.255 (+4.04%)

AMRN Amarin
$6.56 /

+0.255 (+4.04%)

Recommendations
Nike price target raised to $180 from $174 at KeyBanc » 07:56
01/25/21
01/25
07:56
01/25/21
07:56
NKE

Nike

/

+

, FL

Foot Locker

$47.56 /

-0.325 (-0.68%)

, TPR

Tapestry

$34.32 /

+0.57 (+1.69%)

, LB

L Brands

$45.28 /

-0.63 (-1.37%)

KeyBanc analyst Matthew…

KeyBanc analyst Matthew DeGulis raised the firm's price target on Nike (NKE) to $180 from $174 and keeps an Overweight rating on the shares. The analyst notes that data available points to highly discretionary items, like footwear and accessories, taking share following stimulus payments. To the extent that the Biden administration follows through on its incremental $1,400 stimulus payments, which he views as very likely, DeGulis thinks the primary beneficiaries would be Foot Locker (FL), Nike, Tapestry (TPR), and L Brands (LB).

ShowHide Related Items >><<
TPR Tapestry
$34.32 /

+0.57 (+1.69%)

NKE Nike
/

+

LB L Brands
$45.28 /

-0.63 (-1.37%)

FL Foot Locker
$47.56 /

-0.325 (-0.68%)

NKE Nike
/

+

01/22/21 Williams Capital
Nike initiated with a Buy at Williams Trading
12/30/20 Guggenheim
Nike named best apparel idea for 2021 at Guggenheim
12/24/20 UBS
UBS calls Nike top pick, says momentum 'likely not peaked'
12/22/20 Argus
Nike price target raised to $165 from $140 at Argus
FL Foot Locker
$47.56 /

-0.325 (-0.68%)

01/21/21 Deutsche Bank
Foot Locker price target raised to $49 from $38 at Deutsche Bank
01/15/21 B. Riley Securities
Foot Locker upgraded to Buy with $58 target at B. Riley Securities
01/15/21 B. Riley Securities
Foot Locker upgraded to Buy from Neutral at B. Riley Securities
01/07/21
Fly Intel: Top five analyst upgrades
TPR Tapestry
$34.32 /

+0.57 (+1.69%)

01/21/21 Deutsche Bank
Tapestry price target raised to $42 from $28 at Deutsche Bank
01/07/21 JPMorgan
Tapestry price target raised to $40 from $35 at JPMorgan
01/07/21 Barclays
Tapestry upgraded to Overweight from Equal Weight at Barclays
12/30/20 Guggenheim
Tapestry price target raised to $35 from $27 at Guggenheim
LB L Brands
$45.28 /

-0.63 (-1.37%)

01/21/21 Deutsche Bank
L Brands price target raised to $59 from $54 at Deutsche Bank
01/15/21 B. Riley Securities
L Brands price target raised to $55 from $51 at B. Riley Securities
01/14/21 BMO Capital
L Brands price target raised to $64 from $45 at BMO Capital
01/08/21 B. Riley Securities
L Brands price target raised to $51 from $45 at B. Riley Securities
TPR Tapestry
$34.32 /

+0.57 (+1.69%)

NKE Nike
/

+

LB L Brands
$45.28 /

-0.63 (-1.37%)

FL Foot Locker
$47.56 /

-0.325 (-0.68%)

NKE Nike
/

+

LB L Brands
$45.28 /

-0.63 (-1.37%)

TPR Tapestry
$34.32 /

+0.57 (+1.69%)

NKE Nike
/

+

LB L Brands
$45.28 /

-0.63 (-1.37%)

FL Foot Locker
$47.56 /

-0.325 (-0.68%)

TPR Tapestry
$34.32 /

+0.57 (+1.69%)

NKE Nike
/

+

LB L Brands
$45.28 /

-0.63 (-1.37%)

FL Foot Locker
$47.56 /

-0.325 (-0.68%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.